Therapeutic Solutions International (TSOI) Stock Price, News & Analysis

Company Overview

Therapeutic Solutions International, Inc. focuses on immune modulation for the treatment of various specific diseases in the United States. The company develops a range of immune-modulatory agents to cancers, schizophrenia, suicidal ideation, and traumatic brain injury, as well as for daily health. Its flagship products consist of QuadraMune, a patented synergistic blend of pterostilbene, sulforaphane, epigallocatechingallate, and thymoquionone to increase natural killer cell activity and healthy cytokine production. It also produces nutraceuticals, including ProJuvenol, a synergistic blend of complex anti-aging ingredients in capsules; NanoStilbene, a nanoemulsion of nanoparticle pterostilbene; DermalStilbene, a topical form of pterostilbene delivered through spray application onto skin; IsoStilbene, an injectable formulation of pterostilbene; NeuroStilbene, an intranasal form of pterostilbene; NanoPSA, a blend of NanoStilbene and broccoli sprout extracts; and NLRP3 Trifecta, a two-product combo that consists of one bottle of NanoPSA and one bottle of GTE-50 green tea extract. In addition, the company develops therapeutics in chronic traumatic encephalopathy, and traumatic brain injury and lung pathology; and portfolio of immunotherapies that provides dendritic cell vaccines for cancers to Parkinson's disease developed on StemVacs platform. Therapeutic Solutions International, Inc. was founded in 2007 and is headquartered in Elk City, Idaho.

Key Stats

• Today's Range: $0.0002 to $0.0004
• 50-Day Range: N/A
• 52-Week Range: $0.0001 to $0.0013
• Volume: 174.55 million shs
• Average Volume: 36.81 million shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

Therapeutic Solutions International Stock Analysis - MarketRank™

Therapeutic Solutions International scored higher than 10% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: N/A
• Analyst Rating: N/A

Consensus Rating

There is not enough analysis data for Therapeutic Solutions International.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: N/A

Price to Earnings Ratio vs. the Market

The P/E ratio of Therapeutic Solutions International is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Therapeutic Solutions International is -0.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Short Interest

• Score: 4.0 / 5
• Short Interest Level: Healthy

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Therapeutic Solutions International has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Therapeutic Solutions International has recently decreased by 99.81%, indicating that investor sentiment is improving significantly.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Therapeutic Solutions International does not currently pay a dividend.

Dividend Growth

Therapeutic Solutions International does not have a long track record of dividend growth.

Sustainability and ESG

• Score: N/A
• Environmental Score: N/A

Percentage of Shares Shorted

Short Interest Ratio / Days to Cover

Therapeutic Solutions International has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.

Change versus previous month

Short interest in Therapeutic Solutions International has recently decreased by 99.81%, indicating that investor sentiment is improving significantly.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

Therapeutic Solutions International has a news sentiment score of 1.32. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.60 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Therapeutic Solutions International this week, compared to 1 article on an average week.

Company Ownership

• Score: 0.0 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Therapeutic Solutions International insiders have not sold or bought any company stock.

Percentage Held by Institutions

Only 5.62% of the stock of Therapeutic Solutions International is held by institutions.

TSOI Stock Analysis - Frequently Asked Questions

How have TSOI shares performed this year?

Therapeutic Solutions International's stock was trading at $0.0002 at the beginning of 2025. Since then, TSOI shares have increased by 100.0% and is now trading at $0.0004.
View the best growth stocks for 2025 here.

How do I buy shares of Therapeutic Solutions International?

Shares of TSOI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

What other stocks do shareholders of Therapeutic Solutions International own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Therapeutic Solutions International investors own include Creative Medical Technology (CELZ), Hon Hai Precision Industry (HNHPF), Zevra Therapeutics (ZVRA), CAS Medical Systems (CASM), CRISPR Therapeutics (CRSP), Trevena (TRVN) and Alamos Gold (AGI).

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Medical Equipment
• Current Symbol: OTCMKTS:TSOI
• CUSIP: 883378101
• CIK: 1419051
• Web: therapeuticsolutionsint.com
• Phone: (760) 295-7208
• Fax: N/A
• Employees: 3
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A